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optimal management of blood pressure and full renin–an-
giotensin blockade. But since we are not satisfied their
benefit is proven even in that setting, we do not include
corticosteroids in our main treatment recommendations in
the table or abstract of our article. What Dr Locatelli et al.
regard as ‘nihilism’, we regard as pragmatic realism
avoiding a treatment regimen with some toxicity when
evidence in favor of its use is insecure.
Unfortunately, these uncertainties will not easily be
resolved. Modern management with adequate blood
pressure control and renin–angiotensin blockade is redu-
cing proteinuria and slowing the progression of a
significant proportion of patients with IgA nephropathy.
Proof that treatments additional to this regimen are
effective will therefore require larger and more prolonged
treatment trials unless surrogate markers of progression
become more discriminatory, and our ability to define risk
of progression in individual patients becomes more
refined.
1. Locatelli et al. Steroids and IgA nephritis. Kidney Int 2006, in press.
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To the Editor: Gerntholtz et al.1 report their series of kidney
biopsies from Black African human immunodeficiency virus
(HIV)-positive patients, adding to a growing literature
suggesting HIV-associated nephropathy (HIVAN) to be less
common than originally described.2,3 They found HIV
immune complex kidney disease to be as common as
HIVAN, and describe for the first time a ‘ball-in-cup’
appearance on silver-methenamine staining or electron
microscopy caused by subepithelial deposits associated with
basement membrane reaction, placing this lesion as an
intermediate between classical post-infectious and membra-
nous glomerulonephritis.
On review of 10 Black African HIV-positive patients
biopsied in East London after July 2004, we found a similar
prevalence of HIVAN (3/10) and immune complex-mediated
glomerulonephritis with mesangial matrix increase and
crescent formation (3/10). The ‘ball-in-cup’ lesion newly
described as typical of HIV immune complex kidney disease was
apparent in only one of the three such cases on re-examining
renal tissue. Our patients were similar in age (30–45 years),
renal function (creatinine 4627620 mmol/l, mean7s.d.),
serum albumin (2879 g/l), and CD4 count (2107155 co-
pies/ml). HIV viral load was 4.2870.88 106/l, and none
were intravenous drug users or hepatitis B positive.
Unlike the Gerntholtz series in which of those known to
follow-up 58% died, the outcome was generally good (with
universally good response to anti-retroviral drugs). Despite
often advanced presentation, only one patient has died to
date after a mean 46 weeks follow-up, and of two patients
requiring hemodialysis (both with HIVAN), one has since
recovered independent renal function. In Black African
migrants living in London, similar rates of HIVAN and
immune complex-mediated kidney disease are seen to that
described in Johannesburg – the renal and patient outcome is
however very different, emphasizing the importance of
readily available anti-retroviral therapy.
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The kidney biopsy experience of Cove-Smith et al.1 in an
East London setting with Black African human immuno-
deficiency virus (HIV)-positive patients is interesting in its
parallels to ours. We feel that this emphasizes the fact that
not all that is kidney disease in the context of HIV
infection is classic HIV-associated nephropathy. There are
many other forms of renal pathology which occur, empha-
sizing the need for renal biopsy to allow full clarification.
Although detailed histopathological clarification does
not carry proven therapeutic implications at this stage, we
are at present treating all those with HIV-associated
nephropathy and HIV immune complex kidney disease
with angiotensin-converting enzyme inhibitors and anti-
retroviral therapy, regardless of the CD4 count, as we feel
that the virus is involved in the pathophysiology. This
contrasts with our published experience,2 when antiretro-
viral therapies were not used as they were not available to
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us. It is our emerging but distinct impression that our
results are much improved, in agreement with Cove-Smith
et al.1 We would thus argue for these two nephropathies
(HIV-associated nephropathy and HIV immune complex
kidney disease) to be considered World Health Organiza-
tion stage 4 HIV conditions, requiring antiretroviral
therapy treatment in themselves, regardless of other
clinical parameters.
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Aquaporin-1 and sodium
transport in the peritoneal
membrane – need for more
research?
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To the Editor: We read with great interest the article by Ni
et al.1 regarding the pivotal role of aquaporin-1 (AQP1) in
water removal and ultrafiltration during peritoneal dialysis.
Their important findings validate the essential predictions of
the three-pore model theory.
The authors report that AQP1/ mice showed a complete
loss of sodium sieving. However, no correction of sodium
sieving for Naþ diffusion from the circulation was made,
especially since there is a high concentration gradient of
sodium (plasma sodium 152 mM and Naþ D/P at time 0 less
than 0.9).2 Such a correction might have changed their results
and provided some evidence that AQP1 may have a more
complex physiological role than being strictly a water
channel.
A study of our group regarding the in vitro inhibition of
AQP1 by mercuric chloride in the sheep parietal peritoneum
revealed that this inhibition leads to increased ionic
permeability.3 This finding was attributed to a possible
interaction of AQP1 with other solute transporters. This
hypothesis is also supported by the fact that epithelial sodium
channels were upregulated in the collecting duct of AQP1
knockout mice.4
In conclusion, we suggest that immunogold electron
microscopy for sodium transporters would help us clarify
the possible interaction between AQP1 and other solute
transporters and shed light in the mechanisms of water
permeability and ultrafiltration during peritoneal dialysis.
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We thank Dr Liakopoulos and co-workers1 for their
comment about the interpretation of sodium sieving in
the aquaporin-1 (AQP1)-knockout (Aqp1/) mice. So-
dium sieving is a clinically useful, but indirect parameter
to assess free-water transport across the peritoneal
membrane. Our data show a complete lack of sodium
sieving in the Aqp1/ mice, and intermediate values in the
heterozygous Aqp1/þ mice vs wild-type littermates.2 The
correction of sodium sieving for the diffusion of sodium
from the circulation, based on the mass transfer area
coefficient of urate or creatinine, may indeed be important
in clinical situations associated with an increased transport
of small solutes.3 However, this correction has not been
validated in rodent models and is unlikely to have
significant effect on the absence of sodium sieving
observed in Aqp1/ mice, as the transport of small
solutes, the plasma sodium (at 0 and 30 min), and the
osmotic gradient (dialysate/plasma osmolality at 30 min)
are unchanged vs wild-type littermates.2 Furthermore, our
computed simulations of sodium profiles and volume
curves over the first 60 min of the dwell were very close to
the measured data in AQP1 mice, confirming the total lack
of sodium sieving in Aqp1/ mice. Our conclusions about
the essential role of AQP1 in water permeability during
peritoneal dialysis are based on (i) determination of initial
ultrafiltration rate, a direct indicator of solute-free water
transport; (ii) measurement of net ultrafiltration across the
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